stockmarketproxy
/
COGTNasdaq SEC EDGAR

Cogent Biosciences, Inc.

Pharmaceutical Preparations·WALTHAM, MA·FY end 12/31·CIK 1622229
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue——————
Gross Profit——————
Operating Income-$333.4M-$275.9M-$208.1M-$147.8M-$75.6M
Net Income-$328.9M-$255.9M-$192.4M-$140.2M-$72.3M
Operating CF-$264.4M-$207.8M-$153.6M-$118.6M-$58.8M
Capex$1.6M$573.0K$2.8M$6.9M$1.7M
Free Cash Flow-$266.0M-$208.4M-$156.4M-$125.5M-$60.5M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin——————
FCF Margin——————
R&D / Revenue——————
Effective Tax——————
Debt / Equity0.35—————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
COGT
95:1
ROIV
518:1
AXSM
23:1
PFE
277:1
ABT
166:1
PTCT
7:1
CEO total comp
COGT
$28M
ROIV
$163M
AXSM
$34M
PFE
$28M
ABT
$24M
PTCT
$23M
Net Margin
COGT
—
ROIV
-592.0%
AXSM
-28.7%
PFE
12.4%
ABT
14.7%
PTCT
39.4%